Клинические практические рекомендации KDIGO 2025 по ведению иммуноглобулин А нефропатии (IgA-Н) и иммуноглобулин A васкулита (IgA-В). Перевод на русский язык Е.В. Паршиной, Н.М. Буланова и А.А. Ефимовой под редакцией Е.В. Захаровой

Клинические практические рекомендации KDIGO («Инициативы по Улучшению Глобальных Исходов Заболеваний Почек») 2025 по ведению иммуноглобулин A нефропатии (IgA-Н) и иммуноглобулин A васкулита (IgA-В) представляют целенаправленное обновление Главы 2 Клинических практических рекомендаций KDIGO по ведению гломерулярных заболеваний 2021, посвященной иммуноглобулин A нефропатии (IgA-Н) / иммуноглобулин A васкулиту (IgA-В). Их основная цель – помочь врачам, оказывающим помощь лицам с IgA-Н или IgA-В. В ходе подготовки нового варианта были учтены результаты рандомизированных контролируемых исследований, опубликованных с апреля 2023 года, с обновлением в августе 2024 года. Как и в 2021 году, рекомендации представляют руководство по диагностике, оценке прогноза, лечению и действиям в особых ситуациях. Будучи основано на новой доказательной базе, это обновление преимущественно сфокусировано на рекомендациях, относящихся к IgA-Н. Разработка этих рекомендаций стала результатом детального анализа и оценки доказательной базы. Подходы к лечению и рекомендации основаны на систематическом обзоре релевантных исследований и оценке убедительности доказательной базы и силы рекомендаций по системе “Оценки, разработки и оценивания рекомендаций” (GRADE). В рекомендациях обсуждаются ограничения доказательной базы, а также представлены направления будущих исследований.

1. Vivarelli M, Samuel S, Coppo R, et al. IPNA clinical practice recommendations for the diagnosis and management of children with IgA nephropathy and IgA vasculitis nephritis. Pediatr Nephrol. 2025;40:533–569.

2. Bansal B, Grewal A, Teo BW, et al. Clinical practice patterns in IgA nephropathy: a global questionnaire-based survey. Kidney Int Rep. 2023;8:2557–2568.

3. Trimarchi H, Barratt J, Cattran DC, et al. Oxford classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group. Kidney Int. 2017;91:1014–1021.

4. Bartosik LP, Lajoie G, Sugar L, et al. Predicting progression in IgA nephropathy. Am J Kidney Dis. 2001;38:728–735.

5. Berthoux F, Mohey H, Laurent B, et al. Predicting the risk for dialysis or death in IgA nephropathy. J Am Soc Nephrol. 2011;22:752–761.

6. Goto M, Wakai K, Kawamura T, et al. A scoring system to predict renal outcome in IgA nephropathy: a nationwide 10-year prospective cohort study. Nephrol Dial Transplant. 2009;24:3068–3074.

7. Pesce F, Diciolla M, Binetti G, et al. Clinical decision support system for end-stage kidney disease risk estimation in IgA nephropathy patients. Nephrol Dial Transplant. 2016;31:80–86.

8. Wakai K, Kawamura T, Endoh M, et al. A scoring system to predict renal outcome in IgA nephropathy: from a nationwide prospective study. Nephrol Dial Transplant. 2006;21:2800–2808.

9. Xie J, Kiryluk K, Wang W, et al. Predicting progression of IgA nephropathy: new clinical progression risk score. PLoS One. 2012;7:e38904.

10. Tanaka S, Ninomiya T, Katafuchi R, et al. Development and validation of a prediction rule using the Oxford classification in IgA nephropathy. Clin J Am Soc Nephrol. 2013;8:2082–2090.

11. Chen T, Li X, Li Y, et al. Prediction and risk stratification of kidney outcomes in IgA nephropathy. Am J Kidney Dis. 2019;74:300–309.

12. Barbour SJ, Coppo R, Zhang H, et al. Evaluating a new International RiskPrediction Tool in IgA nephropathy. JAMA Intern Med. 2019;179:942–952.

13. Barbour SJ, Coppo R, Er L, et al. Updating the International IgA Nephropathy Prediction Tool for use in children. Kidney Int. 2021;99: 1439–1450.

14. Barbour SJ, Coppo R, Zhang H, et al. Application of the International IgA Nephropathy Prediction Tool one or two years post-biopsy. Kidney Int. 2022;102:160–172.

15. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100:S1–S276.

16. Pitcher D, Braddon F, Hendry B, et al. Long-term outcomes in IgA nephropathy. Clin J Am Soc Nephrol. 2023;18:727–738.

17. Reich HN, Troyanov S, Scholey JW, et al. Remission of proteinuria improves prognosis in IgA nephropathy. J Am Soc Nephrol. 2007;18:3177–3183.

18. Coppo R, Troyanov S, Bellur S, et al. Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments. Kidney Int. 2014;86:828–836.

19. Le W, Liang S, Hu Y, et al. Long-term renal survival and related risk factors in patients with IgA nephropathy: results from a cohort of 1155 cases in a Chinese adult population. Nephrol Dial Transplant. 2012;27:1479–1485.

20. Inker LA, Mondal H, Greene T, et al. Early change in urine protein as a surrogate end point in studies of IgA nephropathy: an individual patient meta-analysis. Am J Kidney Dis. 2016;68:392–401.

21. Thompson A, Carroll K, Inker LA, et al. Proteinuria reduction as a surrogate end point in trials of IgA nephropathy. Clin J Am Soc Nephrol. 2019;14:469481.

22. Selvaskandan H, Shi S, Twaij S, et al. Monitoring immune responses in IgA nephropathy: biomarkers to guide management. Front Immunol. 2020;11:572754.

23. Lafayette R, Barbour S, Israni R, et al. A phase 2b, randomized, doubleblind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy. Kidney Int. 2024;105:1306–1315.

24. Lafayette R, Kristensen J, Stone A, et al. Efficacy and safety of a targetedrelease formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial. Lancet. 2023;402:859–870.

25. Mathur M, Barratt J, Chacko B, et al. A phase 2 trial of sibeprenlimab in patients with IgA nephropathy. N Engl J Med. 2024;390:20–31.

26. Rovin BH, Barratt J, Heerspink HJL, et al. Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial. Lancet. 2023;402:2077–2090.

27. Barratt J, Lafayette R, Kristensen J, et al. Results from part A of the multicenter, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy. Kidney Int. 2023;103:391–402.

28. Fellstrom BC, Barratt J, Cook H, et al. Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial. Lancet. 2017;389:21172127.

29. Stamellou E, Seikrit C, Tang SCW, et al. IgA nephropathy. Nat Rev Dis Primers. 2023;9:67.

30. Wimbury D, Muto M, Bhachu JS, et al. Targeted-release budesonide modifies key pathogenic biomarkers in immunoglobulin A nephropathy: insights from the NEFIGAN trial. Kidney Int. 2024;105:381–388.

31. Lv J, Wong MG, Hladunewich MA, et al. Effect of oral methylprednisolone on decline in kidney function or kidney failure in patients with IgA nephropathy: the TESTING randomized clinical trial. JAMA. 2022;327: 1888–1898.

32. Rauen T, Fitzner C, Eitner F, et al. Effects of two immunosuppressive treatment protocols for IgA nephropathy. J Am Soc Nephrol. 2018;29: 317–325.

33. Rauen T, Wied S, Fitzner C, et al. After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy. Kidney Int. 2020;98:1044–1052.

34. Lv J, Zhang H, Chen Y, et al. Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial. Am J Kidney Dis. 2009;53:26–32.

35. Manno C, Torres DD, Rossini M, et al. Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy. Nephrol Dial Transplant. 2009;24:3694–3701.

36. Lv J, Zhang H, Wong MG, et al. Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: the TESTING randomized clinical trial. JAMA. 2017;318:432–442.

37. Rauen T, Eitner F, Fitzner C, et al. Intensive supportive care plus immunosuppression in IgA nephropathy. N Engl J Med. 2015;373: 2225–2236.

38. Hou JH, Le WB, Chen N, et al. Mycophenolate mofetil combined with prednisone versus full-dose prednisone in IgA nephropathy with active proliferative lesions: a randomized controlled trial. Am J Kidney Dis. 2017;69:788–795.

39. World Health Organization. WHO model list of essential medicines, 20th list (March 2017, amended August 2017). Accessed March 25, 2025. https://iris.who.int/handle/10665/273826

40. Hirano K, Matsuzaki K, Yasuda T, et al. Association between tonsillectomy and outcomes in patients with immunoglobulin A nephropathy. JAMA Netw Open. 2019;2:e194772.

41. Selewski DT, Ambruzs JM, Appel GB, et al. Clinical characteristics and treatment patterns of children and adults with IgA nephropathy or IgA vasculitis: findings from the CureGN Study. Kidney Int Rep. 2018;3: 1373–1384.

42. Yata N, Nakanishi K, Shima Y, et al. Improved renal survival in Japanese children with IgA nephropathy. Pediatr Nephrol. 2008;23:905–912.

43. Tang S, Leung JC, Chan LY, et al. Mycophenolate mofetil alleviates persistent proteinuria in IgA nephropathy. Kidney Int. 2005;68:802–812.

44. Tang SC, Tang AW, Wong SS, et al. Long-term study of mycophenolate mofetil treatment in IgA nephropathy. Kidney Int. 2010;77:543–549.

45. Hou FF, Xie D, Wang J, et al. Effectiveness of mycophenolate mofetil among patients with progressive IgA nephropathy: a randomized clinical trial. JAMA Netw Open. 2023;6:e2254054.

46. Maes BD, Oyen R, Claes K, et al. Mycophenolate mofetil in IgA nephropathy: results of a 3-year prospective placebo-controlled randomized study. Kidney Int. 2004;65:1842–1849.

47. Frisch G, Lin J, Rosenstock J, et al. Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: a double-blind randomized controlled trial. Nephrol Dial Transplant. 2005;20:2139–2145.

48. Hogg RJ, Bay RC, Jennette JC, et al. Randomized controlled trial of mycophenolate mofetil in children, adolescents, and adults with IgA nephropathy. Am J Kidney Dis. 2015;66:783–791.

49. Liu LJ, Yang YZ, Shi SF, et al. Effects of hydroxychloroquine on proteinuria in IgA nephropathy: a randomized controlled trial. Am J Kidney Dis. 2019;74:15–22.

50. Hotta O, Taguma Y, Kurosawa K, et al. Early intensive therapy for clinical remission of active IgA nephropathy: a three-year follow-up study. Nihon Jinzo Gakkai Shi. 1993;35:967–973.

51. Kawamura T, Yoshimura M, Miyazaki Y, et al. A multicenter randomized controlled trial of tonsillectomy combined with steroid pulse therapy in patients with immunoglobulin A nephropathy. Nephrol Dial Transplant. 2014;29:1546–1553.

52. Kawasaki Y, Takano K, Suyama K, et al. Efficacy of tonsillectomy pulse therapy versus multiple-drug therapy for IgA nephropathy. Pediatr Nephrol. 2006;21:1701–1706.

53. Reid S, Cawthon PM, Craig JC, et al. Non-immunosuppressive treatment for IgA nephropathy. Cochrane Database Syst Rev. 2011;16:CD003962.

54. Yang D, He L, Peng X, et al. The efficacy of tonsillectomy on clinical remission and relapse in patients with IgA nephropathy: a randomized controlled trial. Ren Fail. 2016;38:242–248.

55. Kawamura T, Hirano K, Koike K, et al. Associations of corticosteroid therapy and tonsillectomy with kidney survival in a multicenter prospective study for IgA nephropathy. Sci Rep. 2023;13:18455.

56. Kalantar-Zadeh K, Jafar TH, Nitsch D, et al. Chronic kidney disease. Lancet. 2021;398:786–802.

57. Sharma S, Smyth B. From proteinuria to fibrosis: an update on pathophysiology and treatment options. Kidney Blood Press Res. 2021;46:411–420.

58. Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet. 2013;382:339–352.

59. Geng DF, Sun WF, Yang L, et al. Antiproteinuric effect of angiotensin receptor blockers in normotensive patients with proteinuria: a metaanalysis of randomized controlled trials. J Renin Angiotensin Aldosterone Syst. 2014;15:44–51.

60. Nakamura T, Ushiyama C, Suzuki S, et al. Effects of angiotensin-converting enzyme inhibitor, angiotensin II receptor antagonist and calcium antagonist on urinary podocytes in patients with IgA nephropathy. Am J Nephrol. 2000;20:373–379.

61. Li PK, Leung CB, Chow KM, et al. Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study. Am J Kidney Dis. 2006;47:751–760.

62. Jafar TH, Stark PC, Schmid CH, et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med. 2003;139:244–252.

63. Xie X, Atkins E, Lv J, et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet. 2016;387:435–443.

64. Coppo R, Peruzzi L, Amore A, et al. IgACE: a placebo-controlled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria. J Am Soc Nephrol. 2007;18:1880–1888.

65. World Health Organization. The selection and use of essential medicines: report of the WHO Expert Committee, 2017 (including the 20th WHO model list of essential medicines and the 6th model list of essential medicines for children). Accessed March 3, 2025. https://apps.who.int/iris/handle/10665/259481

66. Lennartz DP, Seikrit C, Wied S, et al. Single versus dual blockade of the renin-angiotensin system in patients with IgA nephropathy. J Nephrol. 2020;33:1231–1239.

67. Agodoa LY, Appel L, Bakris GL, et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA. 2001;285:2719–2728.

68. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861–869.

69. Lea J, Greene T, Hebert L, et al. The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American Study of Kidney Disease and Hypertension. Arch Intern Med. 2005;165:947–953.

70. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851–860.

71. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet. 1997;349:1857–1863.

72. Ruggenenti P, Brenner BM, Remuzzi G. Remission achieved in chronic nephropathy by a multidrug approach targeted at urinary protein excretion. Nephron. 2001;88:254–259.

73. Ruggenenti P, Cravedi P, Remuzzi G. Mechanisms and treatment of CKD. J Am Soc Nephrol. 2012;23:1917–1928.

74. Ruggenenti P, Perticucci E, Cravedi P, et al. Role of remission clinics in the longitudinal treatment of CKD. J Am Soc Nephrol. 2008;19:12131224.

75. Ruggenenti P, Schieppati A, Remuzzi G. Progression, remission, regression of chronic renal diseases. Lancet. 2001;357:1601–1608.

76. Heerspink HJL, Radhakrishnan J, Alpers CE, et al. Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial. Lancet. 2023;401:1584–1594.

77. Davenport AP, Hyndman KA, Dhaun N, et al. Endothelin. Pharmacol Rev. 2016;68:357–418.

78. Kohan DE, Barratt J, Heerspink HJL, et al. Targeting the endothelin A receptor in IgA nephropathy. Kidney Int Rep. 2023;8:2198–2210.

79. Nagasawa H, Ueda S, Suzuki H, et al. Sparsentan is superior to losartan in the gddY mouse model of IgA nephropathy. Nephrol Dial Transplant. 2024;39:1494–1503.

80. Inker LA, Collier W, Greene T, et al. A meta-analysis of GFR slope as a surrogate endpoint for kidney failure. Nat Med. 2023;29:1867–1876.

81. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105:S117–S314.

82. Nuffield Department of Population Health Renal Studies Group. SGLT Inhibitor Meta-Analysis Cardio-Renal Trialists’ Consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet. 2022;400:1788–1801.

83. EMPA-KIDNEY Collaborative Group. Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial. Lancet Diabetes Endocrinol. 2024;12: 51–60.

84. The EMPA-KIDNEY Collaborative Group, Herrington WG, Staplin N, Wanner C, et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388:117–127.

85. Heerspink HJL, Stefansson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383:1436–1446.

86. Wheeler DC, Toto RD, Stefansson BV, et al. A pre-specified analysis of the DAPA-CKDtrial indicates effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy. Kidney Int. 2021;388:117–127.

87. Kidney Disease: Improving Global Outcomes (KDIGO) ANCA Vasculitis Work Group. KDIGO 2024 Clinical Practice Guideline for the Management of Antineutrophil Cytoplasmic Antibody (ANCA)Associated Vasculitis. Kidney Int. 2024;105:S71–S116.

88. Su B, Jiang Y, Li Z, et al. Are children with IgA nephropathy different from adult patients? Pediatr Nephrol. 2024;39:2403–2

89. Cambier A, Rabant M, Peuchmaur M, et al. Immunosuppressive treatment in children with IgA nephropathy and the clinical value of podocytopathic features. Kidney Int Rep. 2018;3:916–925.

90. Working Group of the International IgA Nephropathy Network and the Renal Pathology Society, Coppo R, Troyanov S, Camilla R, et al. The Oxford IgA nephropathy clinicopathological classification is valid for children as well as adults. Kidney Int. 2010;77:921–927.

91. Yoshikawa N, Honda M, Iijima K, et al. Steroid treatment for severe childhood IgA nephropathy: a randomized, controlled trial. Clin J Am Soc Nephrol. 2006;1:511–517.

92. Yoshikawa N, Ito H, Sakai T, et al., The Japanese Pediatric IgA Nephropathy Treatment Study Group. A controlled trial of combined therapy for newly diagnosed severe childhood IgA nephropathy. J Am Soc Nephrol. 1999;10:101–109.

93. Coppo R. Biomarkers and targeted new therapies for IgA nephropathy. Pediatr Nephrol. 2017;32:725–731.

94. Haas M, Rahman MH, Cohn RA, et al. IgA nephropathy in children and adults: comparison of histologic features and clinical outcomes. Nephrol Dial Transplant. 2008;23:2537–2545.

95. Kamei K, Nakanishi K, Ito S, et al. Long-term results of a randomized controlled trial in childhood IgA nephropathy. Clin J Am Soc Nephrol. 2011;6:1301–1307.

96. Kawasaki Y, Maeda R, Kanno S, et al. Long-term follow up of pediatric immunoglobulin A nephropathy treated with tonsillectomy plus methylprednisolone pulse therapy. Pediatr Int. 2017;59:41–47.

97. Shima Y, Nakanishi K, Kamei K, et al. Disappearance of glomerular IgA deposits in childhood IgA nephropathy showing diffuse mesangial proliferation after 2 years of combination/prednisolone therapy. Nephrol Dial Transplant. 2011;26:163–169.

98. Yoshikawa N, Ito H. Combined therapy with prednisolone, azathioprine, heparin-warfarin, and dipyridamole for paediatric patients with severe IgA nephropathy—is it relevant for adult patients? Nephrol Dial Transplant. 1999;14:1097–1099.

99. Pozzi C, Andrulli S, Pani A, et al. Addition of azathioprine to corticosteroids does not benefit patients with IgA nephropathy. J Am Soc Nephrol. 2010;21:1783–1790.

100. Pozzi C, Bolasco PG, Fogazzi GB, et al. Corticosteroids in IgA nephropathy: a randomised controlled trial. Lancet. 1999;353:883–887. 100a. Kidney Disease: Improving Global Outcomes (KDIGO) Nephrotic Syndrome In Children Work Group. KDIGO 2025 Clinical Practice Guideline for the Management of Nephrotic Syndrome in Children. Kidney Int. 2025;107(5S):S241–S289.

101. Lv J, Yang Y, Zhang H, et al. Prediction of outcomes in crescentic IgA nephropathy in a multicenter cohort study. J Am Soc Nephrol. 2013;24: 2118–2125.

102. Shima Y, Nakanishi K, Hama T, et al. Spontaneous remission in children with IgA nephropathy. Pediatr Nephrol. 2013;28:71–76.

103. Ozen S, Marks SD, Brogan P, et al. European consensus-based recommendations for diagnosis and treatment of immunoglobulin A vasculitis - the SHARE initiative. Rheumatology (Oxford). 2019;58:1607–1616.

104. Ozen S, Ruperto N, Dillon MJ, et al. EULAR/PReS endorsed consensus criteria for the classification of childhood vasculitides. Ann Rheum Dis. 2006;65:936–941.

105. Ozen S, Pistorio A, Iusan SM, et al. EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: final classification criteria. Ann Rheum Dis. 2010;69:798–806.

106. Coppo R, Andrulli S, Amore A, et al. Predictors of outcome in Henoch-Schönlein nephritis in children and adults. Am J Kidney Dis. 2006;47: 993–1003.

107. Pillebout E, Thervet E, Hill G, et al. Henoch-Schönlein purpura in adults: outcome and prognostic factors. J Am Soc Nephrol. 2002;13:1271–1278.

108. Shrestha S, Sumingan N, Tan J, et al. Henoch Schönlein purpura with nephritis in adults: adverse prognostic indicators in a UK population. QJM. 2006;99:253–265.

109. Barbour SJ, Coppo R, Er L, et al. Histologic and clinical factors associated with kidney outcomes in IgA vasculitis nephritis. Clin J Am Soc Nephrol. 2024;19:438–451.

110. Dudley J, Smith G, Llewelyn-Edwards A, et al. Randomised, double-blind, placebo-controlled trial to determine whether steroids reduce the incidence and severity of nephropathy in Henoch-Schönlein purpura (HSP). Arch Dis Child. 2013;98:756–763.

111. Ronkainen J, Koskimies O, Ala-Houhala M, et al. Early prednisone therapy in Henoch-Schönlein purpura: a randomi placebo controlled trial. J Pediatr. 2006;149:241–247.

112. Hahn D, Hodson EM, Willis NS, et al. Interventions for preventing and treating kidney disease in Henoch-Schönlein purpura (HSP). Cochrane Database Syst Rev. 2015; 2015: CD005128.

113. Huber AM, King J, McLaine P, et al. A randomized, placebo-controlled trial prednisone in early Henoch Schönlein purpura [ISRCTN85109383]. BMC Med. 2004;2:7.

114. Islek I, Sezer T, Totan M, eds. The effect of prophylactic prednisolone therapy on renal involvement in Henoch Schönlein vasculitis [abstract 103]. Abstract presented at: Proceedings of the XXXVI Congress of the European Renal Association European Dialyslsis and Transplant Association. September 5–8, 1999; Madrid, Spain.

115. Mollica F, Li Volti S, Garozzo R, et al. Effectiveness of early prednisone treatment in preventing the development of nephropathy in anaphylactoid purpura. Eur J Pediatr. 1992;151:140–144.

116. Augusto JF, Sayegh J, Delapierre L, et al. Addition of plasma exchange to glucocorticosteroids for the treatment of severe Henoch-Schönlein purpura in adults: a case series. Am J Kidney Dis. 2012;59:663–669.

117. Chartapisak W, Opastiraku S, Willis NS, et al. Prevention and treatment of renal disease in Henoch-Schönlein purpura: a systematic review. Arch Dis Child. 2009;94:132–137.

118. Chartapisak W, Opastirakul S, Hodson EM, et al. Interventions for preventing and treating kidney disease in Henoch-Schönlein purpura (HSP). Cochrane Database Syst Rev. 2009;(3):CD005128.

119. Crayne CB, Eloseily E, Mannion ML, et al. Rituximab treatment for chronic steroid-dependent Henoch-Schönlein purpura: 8 cases and a review of the literature. Pediatr Rheumatol Online J. 2018;16:71.

120. Maritati F, Fenoglio R, Pillebout E, et al. Brief report: rituximab for the treatment of adult-onset IgA vasculitis (Henoch-Schönlein). Arthritis Rheumatol. 2018;70:109–114.

121. Institute of Medicine (IOM). Committee on Standards for Developing Trustworthy Clinical Practice Guidelines. In: Graham R, Mancher M, Miller Wolman D, Greenfield S, Steinberg E, eds. Clinical Practice Guidelines We Can Trust. National Academies Press; 2011.

122. Brouwers MC, Kho ME, Browman GP, et al. AGREE II: advancing guideline development, reporting and evaluation in health care. J Clin Epidemiol. 2010;63:1308–1311.

123. Hahn D, Hodson EM, Willis NS, et al. Corticosteroid therapy for nephrotic syndrome in children. Cochrane Database Syst Rev. 2015;3:CD001533.

124. Larkins NG, Liu ID, Willis NS, et al. Non-corticosteroid immunosuppressive medications for steroid-sensitive nephrotic syndrome in children. Cochrane Database Syst Rev. 2020;4:CD002290.

125. Liu ID, Willis NS, Craig JC, et al. Interventions for idiopathic steroid resistant nephrotic syndrome in children. Cochrane Database Syst Rev. 2019;11:CD003594.

126. Higgins JPT, Thomas J, Chandler J, eds. Cochrane Handbook for Systematic Reviews of Interventions. Wiley; 2019.

127. Guyatt GH, Oxman AD, Schunemann HJ, et al. GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. J Clin Epidemiol. 2011;64:380–382.

128. Natale P, Palmer SC, Ruospo M, et al. Immunosuppressive agents for treating IgA nephropathy. Cochrane Database Syst Rev. 2020;3: CD003965.

129. Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.

130. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–560.

131. Guyatt GH, Oxman AD, Kunz R, et al. GRADE guidelines 6. Rating the quality of evidence—imprecision. J Clin Epidemiol. 2011;64:1283–1293.

132. Brunetti M, Shemilt I, Pregno S, et al. GRADE guidelines: 10. Considering resource use and rating the quality of economic evidence. J Clin Epidemiol. 2013;66:140–150.